English (United States)|Italiano (Italia)
English (United States) | Italiano (Italia)
Article details
25 February 2019 - Italfarmaco launches NUPERAL in Italy, the first drug as fixed combination of doxilamine succinate and pyridoxine hydrochloride authorized for the symptomatic treatment of nausea and vomiting during pregnancy

Nausea and vomiting during pregnancy is a condition that variably occurs, from simple morning sickness to continuous vomiting, reducing pregnant woman quality of life.

Italfarmaco’s Women Health Division, always careful to the health and quality of life of woman, made available to medical doctors Nuperal, the first drug as fixed combination of doxilamine succinate and pyridoxine hydrochloride authorized for the symptomatic treatment of nausea and vomiting during pregnancy.

Nuperal is recommended as first line pharmacological therapy by ACOG (American College of Obstetricians and Gynecologists) guidelines and is classified by FDA (Food and drug Administration) in A category for safety during pregnancy.